三氧化二砷联合全反式维甲酸治疗急性早幼粒细胞白血病的初步观察

目的　观察三氧化二砷 (As2 O3 )联合全反式维甲酸 (ATRA)治疗急性早幼粒细胞白血病(APL)的疗效和不良反应。方法　As2 O3 联合ATRA治疗初治和复发APL患者 2 0例 (可评价的患者 18例 )。治疗方法如下 :As2 O3 (0 .1%溶液 ) 10ml加入 5 0g L葡萄糖溶液 5 0 0ml静脉点滴 ,持续 4～ 6h ,1次 d ;ATRA 2 5mg·m- 2 ·d- 1 ,分 2～ 3次服用。结果　 17例患者获得完全缓解 (CR) ,CR率 94.4%。 14例初治患者均获得CR ,4例复发患者中 3例取得CR。均在 30d内达CR。没有发现明显的不良反应。结论　ATRA联合As2 O3 治疗APL患者不仅能获得好的疗效 ,而且能缩短达CR的时间。     

聚丙烯酰胺水凝胶注射隆乳取出后的乳房形态重塑

目的 探讨聚丙烯酰胺水凝胶取出术后继发乳房畸形重塑效果和方法.方法 聚丙烯酰胺水凝胶注射隆乳术后患者60例,术前均行B超和磁共振成像(MRI)检查,明确注射物的分布层次和周围组织浸润情况,术中依据皮肤弹性、乳房皮下层、腺体层、胸肌层变性程度等,置入吸引器导管,自导管内注入生理盐水,彻底吸出和清除注射物,根据患者意愿及组织受损情况,按个性化选择,分为Ⅰ期或Ⅱ期假体植入,并给予相应治疗.结果 60例,随访3个月至3年,乳房外形良好、假体无疝出、无感染、无切口裂口及双侧乳房不对称等畸形,无包膜挛缩等并发症发生.结论 根据聚丙烯酰胺水凝胶取出术后继发乳房畸形特点,按个性化再选择乳房重塑方法,既可使胸部外形改善,又可避免心理压力,取得满意效果.     

扩张颞顶筋膜瓣覆盖多孔高密度聚乙烯支架全耳廓再造术

目的 探讨采用预制颞顶筋膜瓣置入于残耳乳突区皮下进行扩张,观察以扩张的筋膜瓣覆盖多孔高密度聚乙烯(porous high density polyethylene,Medpor)支架做全耳廓再造术的方法 和效果.方法 30例先天性小耳畸形,手术分两期:Ⅰ期,设计带有颞浅动静脉顶支为血管蒂的预制岛状颞浅筋膜瓣,植入残耳侧乳突区皮下腔穴,然后置入皮肤扩张器进行同期同步扩张;Ⅱ期,将扩张的耳后筋膜皮瓣连带颞浅筋膜瓣掀起,覆盖于Medpor支架上,耳后创面中厚植皮,进行全耳廓再造术.结果 经6个月至3年的随访观察,再造耳廓外形逼真,皮色红润,与周围皮肤颜色无异,其大小、形状、位置与面部协调,与健耳对称,微细结构显示清晰.结论 选用Medpor支架,只要熟悉此材料的生物特性,选择合适的手术操作步骤要点,然后采用预制扩张的耳后筋膜皮瓣连带颞浅筋膜瓣覆盖支架,可将手术并发症减少到最低限度,具有创伤小、操作简单、疗程短、术后效果满意、可避免耳廓外形臃肿或支架外露等优点.耳后筋膜皮瓣与颞浅筋膜瓣两者结合,是目前较为理想的全耳廓再造的一种方法 .     

扩张颞顶筋膜瓣覆盖多孔高密度聚乙烯支架全耳廓再造术

目的 探讨采用预制颞顶筋膜瓣置入于残耳乳突区皮下进行扩张,观察以扩张的筋膜瓣覆盖多孔高密度聚乙烯（porous high density polyethylene,Medpor）支架做全耳廓再造术的方法 和效果.方法 30例先天性小耳畸形,手术分两期：Ⅰ期,设计带有颞浅动静脉顶支为血管蒂的预制岛状颞浅筋膜瓣,植入残耳侧乳突区皮下腔穴,然后置入皮肤扩张器进行同期同步扩张;Ⅱ期,将扩张的耳后筋膜皮瓣连带颞浅筋膜瓣掀起,覆盖于Medpor支架上,耳后创面中厚植皮,进行全耳廓再造术.结果 经6个月至3年的随访观察,再造耳廓外形逼真,皮色红润,与周围皮肤颜色无异,其大小、形状、位置与面部协调,与健耳对称,微细结构显示清晰.结论 选用Medpor支架,只要熟悉此材料的生物特性,选择合适的手术操作步骤要点,然后采用预制扩张的耳后筋膜皮瓣连带颞浅筋膜瓣覆盖支架,可将手术并发症减少到最低限度,具有创伤小、操作简单、疗程短、术后效果满意、可避免耳廓外形臃肿或支架外露等优点.耳后筋膜皮瓣与颞浅筋膜瓣两者结合,是目前较为理想的全耳廓再造的一种方法 .     

203例慢性淋巴细胞白血病患者预后相关因素分析

Objective To explore prognostic factors in patients with chronic lymphocytic leukemia (CLL). Methods Two hundred and three CLL patients in our hospital between 2000 to 2007 were retro-spectively reviewed for prognostic factor analysis. Survival was analysed by Kaplan-Meier analysis, univariate analysis by Log-rank test and multivariate analysis by COX regression model. Results With a median follow-up time of 48.0 (3.0 - 156.0) months, the 5-year overall survival (OS) rate was (87.3 ± 2.4) % and 10-year OS rate was (77.4 ± 3.3) %. Forty-eight (23.6%) patients died. Univariate analysis indicated that ad-vanced clinical stage, B symptoms, extranodal involvement, number of lymph node regions involved ≥3, en-larged liver, Hb < 100 g/L, BPC < 100 × 109/L, absolute lymphocyte count (ALC) > 50 × 109/L, atypical cell morphology, progression to stage, non-respons to treatment, complicating infections and secondary cancer or disease transformation were associated with poor prognosis. And on multivariate analysis, lymph node re-gion involvod≥3 and atypical cell morphology were independent poor prognostic factors. Based on the two in-dependent poor prognostic factors, three risk groups were defined: low- (0 factor), intermediate-(one factor) and high-(two factors) groups. The 5 year OS rates were (89.8 ± 3.5) % , (66.4 ～ 7.2) % and (15.0 ±13.8)%, respectively, and the difference between them was statistically. Conclusion The number of lymph node region involved and cell morphology are useful for assessing CLL patients prognosis.     

203例慢性淋巴细胞白血病患者预后相关因素分析

Objective To explore prognostic factors in patients with chronic lymphocytic leukemia (CLL). Methods Two hundred and three CLL patients in our hospital between 2000 to 2007 were retro-spectively reviewed for prognostic factor analysis. Survival was analysed by Kaplan-Meier analysis, univariate analysis by Log-rank test and multivariate analysis by COX regression model. Results With a median follow-up time of 48.0 (3.0 - 156.0) months, the 5-year overall survival (OS) rate was (87.3 ± 2.4) % and 10-year OS rate was (77.4 ± 3.3) %. Forty-eight (23.6%) patients died. Univariate analysis indicated that ad-vanced clinical stage, B symptoms, extranodal involvement, number of lymph node regions involved ≥3, en-larged liver, Hb < 100 g/L, BPC < 100 × 109/L, absolute lymphocyte count (ALC) > 50 × 109/L, atypical cell morphology, progression to stage, non-respons to treatment, complicating infections and secondary cancer or disease transformation were associated with poor prognosis. And on multivariate analysis, lymph node re-gion involvod≥3 and atypical cell morphology were independent poor prognostic factors. Based on the two in-dependent poor prognostic factors, three risk groups were defined: low- (0 factor), intermediate-(one factor) and high-(two factors) groups. The 5 year OS rates were (89.8 ± 3.5) % , (66.4 ～ 7.2) % and (15.0 ±13.8)%, respectively, and the difference between them was statistically. Conclusion The number of lymph node region involved and cell morphology are useful for assessing CLL patients prognosis.     

43例淋巴母细胞淋巴瘤患者临床特点及疗效分析

Objective To investigate the clinical features and treatment outcomes of different regimens in Chinese patients with lymphoblastic lymphoma(LBL). Methods Forty-three patients with LBL were retrospectively analysed, of which 30 were T-LBL, and 13 B-LBL. Results ①Most patients were young men with a median age of 21, and 63.0％ of the T-LBL patients had mediastinal masses. ② Treatment outcome could be assessed in 37 cases, of which the response rate (RR) was 81.1％ and complete remission (CR) rate was 67.6％. The RR and CR rates in patients treated with regimens for ALL (ALL-like group) and those treated with regimens for NHL(NHL-like group) were 94.4％ , 68.4％ and 83.3％ , 52.6％ , respectively. ③The estimated median overal survival(OS) and progression free survival (PFS) of hematopoietic stem cell transplantation (HSCT) group were significant longer than those of ALL-like group(P =0.018, P=0.025) and NHL-like group(P = 0. 016, P = 0. 011). The OS at 5 years in NHL-like group, ALL-like group and HSCT group were (14.4 ± 9.4) ％ , (20.2 ± 12.7) ％ and (79.5 ± 13.1) ％, respectively. Conclusion ①LBL is more common in young men, with less involvement of peripheral blood. Compared with B-LBL, T-LBL often has a mediastinal mass and serious cavity effusion. ② Intensive treatment regimens for ALL should be used in LBL. HSCT at CR1 can improve outcome obviously.     

急性白血病诱导化疗合并院内感染100例临床分析

急性白血病诱导化疗合并院内感染１００例临床分析中国医学科学院血液学研究所血液病医院（３０００２０）薛艳萍卞寿庚赵耀中周世勇魏晓溪陈玉梅急性白血病（ＡＬ）诱导治疗中的两大死亡原因是出血和感染，特别是院内感染是影响ＡＬ疗效及生存期的一大问题。现将我院住院...     

硼替佐米为主的联合化疗方案加或不加造血干细胞移植治疗多发性骨髓瘤疗效分析

目的 观察以硼替佐米为主的联合化疗方案加或不加造血干细胞移植(SCT)治疗多发性骨髓瘤(multiple myeloma,MM)患者的疗效及不良反应.方法 31例初治或复发(难治)MM患者接受硼替佐米为主治疗.之后有6例患者接受SCT治疗.按照EBMT标准评价疗效,WHO标准判断不良反应.结果 ①有5例患者由于急性肾功能衰竭、肿瘤溶解综合征等原因终止治疗,其中3例死亡.可以统计疗效的26例患者共完成了99个疗程的治疗,总有效率(ORR)为80.8%.15例初治患者的ORR为100.0%.11例复发(难治)患者的ORR为54.6%.②15例初治患者中有7例完成了8个疗程的治疗,动态观察发现随着疗程的延长疗效不断提高.③6例初治患者化疗达完全缓解(CR)或接近CR(mCR)后行SCT治疗,其中1例复发,5例随访至移植后6～11个月仍持续CR.未采取SCT巩固的9例初治患者中除1例持续CR外有6例在停药后1～3个月复发或进展,2例失访.④多数治疗相关不良反应为l～2级,有3例患者因为末梢神经炎、窦性心动过缓等原因降低硼替佐米的用量,5例因严重不良反应终止治疗.结论 硼替佐米治疗初治及复发(难治)MM疗效肯定,但可能需要进行巩固治疗(如SCT)以维持疗效.硼替佐米不良反应多数轻微且可以耐受,但也应注意少见的严重不良反应.     

增生性瘢痕组织中肿瘤坏死因子α R1 mRNA的表达及意义

目的：从基因水平探讨肿瘤坏死因子受体(TNF-α R1)在增生性瘢痕组织发生、发展过程中的作用，为增生性瘢痕的基因治疗探索一条有效途径。方法：以正常瘢痕为对照，利用RT-PCR技术检测1年以上增生性瘢痕组织成纤维细胞中TNF-α R1 mRNA的表达情况。结果：1年以上增生性瘢痕组织中TNF-α R1 mRNA的表达稳定，与正常瘢痕比较含量明显下降。结论：增生性瘢痕的形成与TNF-α R1的表达低下有一定关系。用基因治疗的方法提高早期增生性瘢痕中TNF-α的含量或者提高靶细胞膜上TNF-α R1的数目与活性可能为增生性瘢痕的康复治疗的有效途径。